ArticleFrontiers in oncology2021

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.

Tomás Pascual et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.